Most telehealth brands should consider buying pharmacy connectivity, normalized statuses, webhooks, and basic routing controls. That leaves their team to build the rules and patient experience specific to the business. Building every pharmacy integration in-house can make sense when fulfillment logic is a core competitive advantage, transaction volume supports a dedicated integration team, and the brand is willing to own continuous pharmacy-by-pharmacy maintenance.
A multi-pharmacy program rarely starts as an architecture debate. It starts with a practical request: add a second pharmacy, launch in more states, create a backup for stockouts, or route patients to a lower-cost option. The first direct integration often feels manageable. The third or fourth reveals the real problem.
Each pharmacy may use different identifiers, prescription intake methods, status terms, validation rules, refill behavior, error messages, support processes, and release schedules. A telehealth company is no longer maintaining an integration. It is operating a small network.
That is the build-versus-buy decision: which parts of that network should your team own?
The four decisions hiding inside build vs. buy
Leaders often treat the question as one binary choice. In practice, it contains four separable decisions:
- Connectivity: How do orders reach each pharmacy?
- Normalization: How are different pharmacy objects and statuses converted into one internal model?
- Routing: Which eligible pharmacy should receive a given prescription?
- Operations: Who detects, investigates, and resolves failures after launch?
You can buy one layer and build another. The most resilient architecture is frequently hybrid.
Layer | Good candidate to buy | Good candidate to build |
|---|---|---|
| Pharmacy connectivity | Connectors, authentication, endpoint changes, transport retries | A unique or strategic pharmacy integration unavailable elsewhere |
| Data normalization | Standard order, patient, product, price, and status objects | Brand-specific clinical or commercial metadata |
| Routing | Configurable rules engine, eligibility filters, audit trail | Proprietary optimization logic and business constraints |
| Operations | Monitoring, webhook delivery, integration support | Patient-facing workflows and internal escalation policies |
Option 1: build direct pharmacy integrations
In a direct model, your engineering team connects separately to each pharmacy or dispensing partner. The telehealth platform owns the contract between its internal prescription model and every external endpoint.
Where direct integrations are strongest
Direct integrations can provide maximum control. Your team decides the payload, retry behavior, status model, monitoring, and release cadence. You are not constrained by a network vendor's abstraction or roadmap.
This model can be rational when:
- one or two pharmacy relationships account for nearly all volume;
- the pharmacy exposes a mature, stable API with strong documentation;
- fulfillment behavior is central to the product's differentiation;
- your internal team already has healthcare-integration and production-operations expertise;
- the business can justify permanent engineering ownership, not just an initial project;
- a required workflow is too specialized for available platforms.
Direct connectivity may also reduce dependency on an intermediary. But fewer vendors does not automatically mean less operational complexity: the complexity moves into your own codebase and on-call rotation.
The costs teams underestimate
The build estimate often covers the happy path: create an order, receive a status, and test a cancellation. Production ownership is broader.
A credible estimate should include:
- pharmacy discovery and technical diligence;
- data mapping and validation;
- identity and address edge cases;
- product, dosage-form, strength, and quantity normalization;
- state and formulary eligibility;
- authentication and key rotation;
- idempotency and duplicate prevention;
- webhook verification and replay handling;
- polling where webhooks are incomplete;
- retries, dead-letter handling, and reconciliation;
- monitoring, dashboards, and alerting;
- sandbox limitations and certification;
- pharmacy release changes;
- support tooling and audit history;
- security review, access control, and incident response;
- launch management and ongoing regression testing.
The largest cost usually arrives after integration complete. Every additional pharmacy multiplies the combinations that quality assurance and operations must understand.
Option 2: buy a pharmacy-routing platform
A routing or orchestration platform places a normalized layer between the telehealth application and multiple pharmacies. The brand integrates once with the platform, configures eligible partners and rules, and receives a common set of status events.
Where a platform is strongest
Buying is attractive when speed, breadth, and reduced connector maintenance matter more than total control over every pharmacy-specific detail.
It is usually the better starting point when:
- the roadmap calls for several pharmacies or frequent network changes;
- state coverage, formulary, inventory, price, or service level affects routing;
- the company has a lean engineering team;
- pharmacy integrations are necessary infrastructure rather than the core product;
- operations needs one view across partners;
- leadership wants failover without writing a new integration for every backup;
- the platform can prove access to the pharmacies and workflows you actually need.
A platform should not be judged by the phrase "single API" alone. The real question is how much heterogeneity it successfully absorbs. Ask whether it normalizes acknowledgments, exceptions, refill events, cancellations, tracking, payment responsibilities, and support alongside order submission.
The costs teams underestimate
Buying introduces its own obligations:
- vendor and network dependency;
- implementation and transaction fees;
- possible limits on customization;
- a common data model that may hide pharmacy-specific details;
- migration and data-portability concerns;
- contract alignment across the platform and pharmacies;
- the need to verify routing behavior rather than treating it as a black box.
A platform reduces integration work; it does not eliminate your responsibility for clinical appropriateness, patient consent, pharmacy eligibility, privacy, security, or operational oversight.
Option 3: use a hybrid architecture
A hybrid model buys network connectivity and normalized orchestration while keeping the brand's proprietary decision logic, patient experience, and analytics in-house.
A common pattern is:
- the telehealth application creates a normalized prescription request;
- the brand's eligibility service applies clinical, patient-choice, and contractual constraints;
- the routing platform evaluates current pharmacy capabilities and operational rules;
- the selected pharmacy receives the order;
- normalized events return to the brand's workflow engine;
- raw partner details remain available for investigation.
This preserves flexibility without turning every connector into an internal product.
Hybrid architecture can also be selective. A high-volume strategic pharmacy may stay direct, while a network platform supplies geographic coverage, specialty capabilities, or redundancy. If you choose this model, define a single internal order and status model so the rest of your application does not care which connection path was used.
A decision framework that produces a real answer
Score the following dimensions from 1 to 5. Do not average them blindly; mark any non-negotiable requirement as a gate.
Dimension | Build leans stronger when… | Buy leans stronger when… |
|---|---|---|
| Time to launch | Roadmap can absorb a longer program | Expansion timing is measured in weeks or a few months |
| Pharmacy count | One or two stable partners | Several partners or frequent additions |
| Workflow uniqueness | Fulfillment logic is deeply proprietary | Most needs fit configurable rules |
| Engineering capacity | Dedicated integration and SRE ownership exists | Team must stay focused on clinical and patient product |
| Change frequency | Partners and requirements are stable | Formularies, coverage, availability, or vendors change often |
| Observability | You can build cross-partner tooling | You need normalized monitoring out of the box |
| Control | Direct access to every implementation detail is essential | Abstraction and portability are more valuable |
| Economics | Sustained volume supports fixed ownership cost | Variable cost and faster deployment are preferable |
| Vendor risk | Internal ownership is strategically required | Vendor diligence and exit rights can control dependency |
| Compliance operations | Internal teams already operate the required controls | Vendor evidence and shared workflows reduce duplication |
Model total cost of ownership, not the project quote
Use a three-year view.
Build TCO = initial engineering + partner onboarding + infrastructure + security/compliance + quality assurance + support tooling + ongoing maintenance + incident cost + opportunity cost
Buy TCO = implementation + platform/transaction fees + internal integration + vendor management + pharmacy contracts + change requests + migration/exit preparation
Opportunity cost matters. If six months of engineering delays a revenue-generating program or prevents a patient-experience improvement, that belongs in the build calculation. Conversely, if a platform prevents a strategically important workflow, that constraint belongs in the buy calculation.
Do not publish a single ROI number unless the inputs are documented. Build scenario ranges for low, expected, and high volume, and test what happens when you add two more pharmacies.
What to request in vendor diligence
Before selecting a platform, ask for evidence rather than adjectives.
Request:
- the exact pharmacy and state coverage relevant to your launch;
- supported dosage forms, products, and prescription workflows;
- an event and status dictionary;
- API and webhook documentation;
- retry, idempotency, reconciliation, and downtime procedures;
- pharmacy onboarding process and typical dependencies;
- rule configuration, versioning, testing, and audit logs;
- data export and termination assistance;
- subprocessor, security, and incident-response documentation;
- named support ownership and severity-based response expectations;
- references from comparable telehealth programs.
Run a proof of concept with realistic exceptions. A successful demo should include an ineligible state, unsupported formulation, duplicate submission, delayed acknowledgment, cancellation, inventory failure, and pharmacy outage.
What to build even when you buy
A canonical internal model
Your application should have stable identifiers and definitions for patient, prescriber, prescription, product, pharmacy, shipment, payment, and status. Vendor-specific values should map into this model at the boundary.
A policy layer
Document which constraints are clinical, legal, patient-driven, contractual, financial, or operational. Patient choice and clinician intent should not be silently subordinated to margin or speed.
Independent observability
Retain enough event data to calculate acknowledgment time, exception rate, fulfillment cycle time, cancellation rate, webhook completeness, and failover frequency by pharmacy. A vendor dashboard is useful; an exportable source of truth is safer.
An exit path
Know how you would retrieve open orders, historical events, configuration, and audit records. Keep the internal API boundary clean enough that another platform or a direct connector can be introduced without rewriting the patient product.
Recommended decision by company stage
Early-stage telehealth brand
Buy or use a hybrid. Preserve engineering capacity for clinical workflows, acquisition, retention, and patient support. Insist on exportability and transparent rules.
Scaling multi-state brand
Use a platform for coverage and normalization, while owning your routing policy, analytics, and patient experience. Consider a direct connection only for a strategic partner where volume and workflow depth justify it.
Large enterprise with dedicated integration teams
Evaluate a portfolio approach. Direct integrations may be economical for anchor pharmacies, while an orchestration layer handles the long tail, redundancy, and future additions.
A 90-day evaluation sequence
Weeks 1 to 2: Define the operating model. Document the intended pharmacy roster, states, formulations, patient-choice workflow, status requirements, support model, and non-negotiable controls.
Weeks 3 to 4: Compare architectures. Create build, buy, and hybrid diagrams; estimate three-year TCO; identify single points of failure.
Weeks 5 to 8: Run proofs of concept. Test at least two pharmacy paths and the exception cases that matter most.
Weeks 9 to 10: Validate operations and security. Conduct tabletop incidents, review data flows, and verify reporting.
Weeks 11 to 12: Decide with gates. Choose based on proven coverage, reliability, controllability, economics, and exit readiness.
Frequently asked questions
Is building always cheaper at high volume?
No. High volume can improve internal economics, but it also increases the cost of downtime, reconciliation, support, and change management. The answer depends on pharmacy count, workflow complexity, engineering cost, and platform pricing.
Will a routing platform replace an EHR or e-prescribing system?
Usually not. E-prescribing, clinical documentation, pharmacy selection, routing orchestration, dispensing, and patient engagement are distinct layers. Confirm exactly where each system's responsibility begins and ends.
Should we keep one direct pharmacy connection as a backup?
It can be useful, but only if the backup path is continuously tested and operationally supported. Dormant failover code is not reliable redundancy.
What is the most common mistake?
Treating launch as the finish line. The durable work is monitoring, exception handling, partner changes, and keeping the routing policy accurate.
Bottom line
For most multi-pharmacy telehealth brands, the optimal answer is neither "build everything" nor "outsource everything." Buy the repeatable network plumbing. Build the policy, data, patient experience, and differentiated logic that are uniquely yours. Choose direct integrations selectively, with a full view of their lifetime operating cost.
Compounded drugs are not FDA-approved, and federal and state oversight differs by pharmacy type and activity. Architecture decisions should be reviewed with qualified legal, compliance, clinical, privacy, and security professionals. This article is general information, not legal, medical, or regulatory advice. See the FDA's compounding Q&A.